Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

tax expense

(1)0.61.1(222.0)(7.0)(227.3) 15 Depreciation3.43.74.24.415.7 24 Amortization0.10.91.01.03.0 4 EBITDA (Loss)6.56.82.5(12.4)3.4 (11) - 1 Stock-based compensation8.59.210.09.837.5 43 Gain on sale of equity investments(0.9)---(0.9) — Contingent consideration

(2)0.70.83.1(0.6)4.0 11 Material non-recurringConvertible debt exchange

(3)---13.713.7 — Acquisition expenses

(4)--1.8-1.8 — Adjusted EBITDA$
4.8$   16.8$
7.4$
.5$
59.5 $43 - $55 (1)  Includes the release of the Company's income tax valuation allowance during 2010.(2)  Represents the changes in the fair value of contingent acquisition consideration payable for the period.   (3)   Represents debt conversion expense associated with the early conversion of a portion our convertible debt in November 2010.(4)   Represents transactions costs associated with the acquisition of ZyStor Therapeutics Inc., during the third quarter of 2010.   Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDAFor the Four Quarters and Fiscal Year 2009(in millions)(unaudited) 2009Three Months EndedYear Ended DecemberNOTESMarch 31June 30September 30December 3131, 2009GAAP Net Income/(Loss)$
(13.1)$
.3$
.6$
4.7$
(0.5)Interest expense, net1.93.51.91.79.0Income tax expense0.40.50.9(0.8)1.0Depreciation2.83.22.43.111.5Amortization1.21.90.20.23.5EBITDA (Loss)(6.8)10.412.08.924.5Stock-based compensation7.89.08.98.834.5Gain on sale of equity investments-(1.6)--(1.6)Material non-recurringUpfront license fees

(1)8.8---8.8Impairment charges

(2)5.9---5.9Adjusted EBITDA$
5.7$   17.8$
20.9$
7.7$
72.1(1)  Represents upfront license payments related to our collaboration agreement with La Jolla Pharmaceutical Company in the first quarter of 2009.   (2)  Includes impairment losses on investments in Summit plc. and La Jolla Pharmaceutical Company recognized during the first quarter
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Depression Therapeutics ... 2018 http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Market Forecasts to 2018 ...
... Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par ... announced that it filed a declaratory judgment complaint and ... in Washington, D.C. seeking to preserve Par,s First Amendment ... healthcare providers about the FDA-approved, on-label use of Par,s ...
Cached Medicine Technology:Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 2Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 3Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 4
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... July 28, 2014 Maternal and Family ... Tucker Award, which will be presented at the agency’s ... October 29th at the Westmoreland Club in Wilkes-Barre. , ... Commissioner and long-time employee of MFHS. She dedicated ... political activist, health advocate, and champion for women, children ...
(Date:7/28/2014)... that following a healthy lifestyle may lower childhood cancer ... online in CANCER , a peer-reviewed journal of ... with cancer and adults who had cancer when they ... may influence their long-term health. , Adults who ... increased risk for the metabolic syndrome, a group of ...
(Date:7/28/2014)... As health insurers design their strategies ... exchanges. “Private Exchange Strategies for Insurers: What’s Working? ... Information Services, will provide answers to the big-dollar questions ... future. , Barbara Gniewek, Jonathan Har-Even and Martin Hill ... the private exchange sector — will provide expert presentations ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... nerve fibers regenerate, researchers say , FRIDAY, Dec. 11 (HealthDay ... enables regeneration of injured nerve fibers (axons) in mice, a ... treatments for people with brain and spinal cord injuries. , ... an inhibitor of a growth pathway called mTOR -- in ...
... H1N1 activity, down from 25 states last week, CDC says ... rates continue to drop, U.S. health officials said Friday, with ... states last week and 48 states at the height of ... influenza viruses identified so far continue to be H1N1 swine ...
... , , ABBOTT PARK, Ill., Dec. 11 ... declared a quarterly common dividend of 40 cents per share. , ... since 1924. The cash dividend is payable Feb. 15, 2010, to ... , Abbott has increased its dividend payout for 37 consecutive years - ...
... , , Linton Whitaker, ... 11 Linton Whitaker, M.D., a craniofacial surgeon at The ... recently awarded the prestigious Paul Tessier Medal during the annual ... England. , The Paul Tessier Medal is the highest honor ...
... , , AUSTIN, Texas, ... Medical Solutions, is pleased to offer free upgrades to their customers ... Dragon Medical 10.1 is faster and more stable, providing up ... and is compliant with Windows7, 64bit and 32bit operating systems. New ...
... Ill., Dec. 11 If you have a foot or ankle ... every five Americans suffer some sort of foot problem. These problems ... as pain in the knee, hip or back. , How ... If they hurt, they may be signaling more serious conditions. They ...
Cached Medicine News:Health News:New Hope for Brain, Spinal Cord Injuries 2Health News:Swine Flu Infection Rates Continue to Fall 2Health News:Swine Flu Infection Rates Continue to Fall 3Health News:Children's Hospital Surgeon Receives Prestigious Paul Tessier Medal 2Health News:Recorders.com Offers Free Dragon Medical 10.1 Upgrades 2Health News:Happy Feet are Healthy Feet: Common Sense Tips on Taking Care of Your Feet to Survive the Holiday Season 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: